Themis Medicare Adjusts Valuation Amidst Competitive Pharmaceutical Landscape Changes

Themis Medicare, a small-cap player in the Pharmaceuticals & Drugs sector, has recently undergone a valuation adjustment. The company's current price stands at 125.00, reflecting a notable shift from its previous close of 115.80. Over the past year, Themis Medicare has experienced a decline of 42.58%, contrasting sharply with a marginal increase of 0.16% in the Sensex during the same period.
Key financial metrics for Themis Medicare include a PE ratio of 24.94 and an EV to EBITDA ratio of 18.93, which position it within a competitive landscape. The company's return on equity (ROE) is reported at 12.86%, while its return on capital employed (ROCE) stands at 11.06%.

In comparison to its peers, Themis Medicare's valuation metrics reveal a diverse industry landscape. For instance, Innova Captab shows a significantly higher PE ratio of 39.08, while Unichem Labs and Orchid Pharma are positioned at 45.15 and 32.79, respectively. This context highlights the varying financial health and market positioning among companies in the sector, underscoring the competitive dynamics at play.